Table 1

Demographic, genetic and biochemical data

 Age (years)Median (IQR)72 (64–77)72 (66 to 77)66 (59–70)58 (51–64)59 (46–64)68 (62–73)
 MMSE scoreMedian (IQR)23 (19–25)28 (27 to 29)NANA28 (27–29)NA
 MoCA scoreMedian (IQR)NANA30 (28–30)NANA29 (27–29)
 APOE ε4 −/−No.124NANA6NA
 APOE ε4 +/−No.194NANA2NA
 APOE ε4 +/+No.101NANANANA
Blood and CSF samplesNo.4012NA2114NA
Blood samples onlyNo.58950NA1419
 Aβ42 (pg/mL)Median (IQR)504 (424–652)745 (489 to 1191)NA1034 (917–1225)1093 (823–1248)NA
 T-tau (pg/mL)Median (IQR)627 (409–920)382 (243 to 683)NA215 (171–328)174 (117–272)NA
 P-tau (pg/mL)Median (IQR)89 (67–117)56 (43 to 83)NANA39 (29–45)NA
 Aβ42//Aβ40-ratioMedian (IQR)0.5 (0.4–0.7)0.7 (0.5 to 1.0)NANA1.0 (0.8–1.2)NA
 Albumin CSF/blood ratioMedian (IQR)5.9 (4.3–7.2)6.6 (5.3 to 9.0)NA6.1 (5.0–6.9)7.1 (5.2–9.3)NA
  • Demographic, genetic and biochemical data are shown for every diagnostic group. Control patients are further subdivided into healthy volunteers, patients with tension-type headaches, patients with psychiatric diagnoses, namely affective disorders (n=24), neurotic or stress related disorders (n=1), or schizophrenia (n=3), or patients with Parkinson’s disease (PD).

  • AD, Alzheimer’s disease; Aβ42 or 40, β-amyloid 42 or 40; CON, controls; CSF, cerebrospinal fluid; Headache, patients with tension-type headache; Healthy, healthy volunteers; IQR, interquartile range; MCI, mild cognitive impairment due to AD; MMSE, mini mental state examination; MoCA, Montreal Cognitive Assessment; NA, not available; PD, patients with Parkinson’s disease; Psychiatric, patients with psychiatric diagnoses; P-tau, phosphorylated tau; T-tau, total tau.